Momenta Pays Out On Enoxaparin Shut-Out
Settles Class-Action Purchasers’ Suit
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.
You may also be interested in...
Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.
The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.